Copyright © 2010 Kristen M. Drescher et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. S. Warthin, “Hereditary with reference to carcinoma as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895–1913,” Archives of Internal Medicine, vol. 12, pp. 546–555, 1913.
2. H. T. Lynch, M. W. Shaw, C. W. Magnuson, A. L. Larsen, and A. J. Krush, “Hereditary factors in cancer. Study of two large midwestern kindreds,” Archives of Internal Medicine, vol. 117, no. 2, pp. 206–212, 1966. View at Publisher · View at Google Scholar · View at Scopus
3. H. T. Lynch and A. J. Krush, “Cancer family "G" revisited: 1895–1970,” Cancer, vol. 27, no. 6, pp. 1505–1511, 1971. View at Scopus
4. S. N. Thibodeau, G. Bren, and D. Schaid, “Microsatellite instability in cancer of the proximal colon,” Science, vol. 260, no. 5109, pp. 816–819, 1993. View at Scopus
5. Y. Ionov, M. A. Peinado, S. Malkhosyan, D. Shibata, and M. Perucho, “Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis,” Nature, vol. 363, no. 6429, pp. 558–561, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. L. A. Aaltonen, P. Peltomaki, and P. Peltomaki, “Clues to the pathogenesis of familial colorectal cancer,” Science, vol. 260, no. 5109, pp. 812–816, 1993. View at Scopus
7. R. H. Sijmons, L. A. L. M. Kiemeney, J. A. Witjes, and H. F. A. Vasen, “Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options,” Journal of Urology, vol. 160, no. 2, pp. 466–470, 1998. View at Publisher · View at Google Scholar · View at Scopus
8. M. Aarnio, J.-P. Mecklin, L. A. Aaltonen, M. Nystrom-Lahti, and H. J. Jarvinen, “Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome,” International Journal of Cancer, vol. 64, no. 6, pp. 430–433, 1995. View at Publisher · View at Google Scholar · View at Scopus
9. P. Watson, H. F. A. Vasen, J. P. Mecklin, H. Järvinen, and H. T. Lynch, “The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer,” American Journal of Medicine, vol. 96, no. 6, pp. 516–520, 1994. View at Publisher · View at Google Scholar · View at Scopus
10. P. Watson, H. F. A. Vasen, and H. F. A. Vasen, “The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome,” International Journal of Cancer, vol. 123, no. 2, pp. 444–449, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. P. Watson, K. M. Lin, and K. M. Lin, “Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members,” Cancer, vol. 83, no. 2, pp. 259–266, 1998. View at Publisher · View at Google Scholar · View at Scopus
12. H. F. A. Vasen, G. J. A. Offerhaus, and G. J. A. Offerhaus, “The tumour spectrum in hereditary non-polyposis colorectal cancer: a study of 24 kindreds in The Netherlands,” International Journal of Cancer, vol. 46, no. 1, pp. 31–34, 1990. View at Publisher · View at Google Scholar · View at Scopus
13. P. Watson and H. T. Lynch, “Extracolonic cancer in hereditary nonpolyposis colorectal cancer,” Cancer, vol. 71, no. 3, pp. 677–685, 1993. View at Publisher · View at Google Scholar · View at Scopus
14. H. F. A. Vasen, J. T. Wijnen, and J. T. Wijnen, “Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis,” Gastroenterology, vol. 110, no. 4, pp. 1020–1027, 1996. View at Publisher · View at Google Scholar · View at Scopus
15. H. F. A. Vasen, E. A. C. M. Sanders, and E. A. C. M. Sanders, “The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC),” International Journal of Cancer, vol. 65, no. 4, pp. 422–425, 1996. View at Publisher · View at Google Scholar · View at Scopus
16. H. F. A. Vasen, H. Morreau, and J. W. R. Nortier, “Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?” American Journal of Human Genetics, vol. 68, no. 6, pp. 1533–1535, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. J. Boyd, E. Rhei, and E. Rhei, “Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome,” Breast Cancer Research and Treatment, vol. 53, no. 1, pp. 87–91, 1999. View at Publisher · View at Google Scholar · View at Scopus
18. H. Kinoshita, A. Yanagisawa, T. Watanabe, H. Nagawa, M. Oya, Y. Kato, and T. Muto, “Increase in the frequency of K-ras codon 12 point mutation in colorectal carcinoma in elderly males in Japan: the 1990s compared with the 1960s,” Cancer Science, vol. 96, no. 4, pp. 218–220, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. J.-T. Liang, Y.-M. Cheng, K.-J. Chang, C.-T. Chien, and H. C. Hsu, “Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection,” Hepato-Gastroenterology, vol. 46, no. 26, pp. 830–837, 1999. View at Scopus
20. T. Enomoto, M. Fujita, M. Inoue, J. M. Rice, R. Nakajima, O. Tanizawa, and T. Nomura, “Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium,” Cancer Research, vol. 53, no. 8, pp. 1883–1888, 1993. View at Scopus
21. R. J. C. Slebos, R. E. Kibbelaar, and R. E. Kibbelaar, “K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung,” New England Journal of Medicine, vol. 323, no. 9, pp. 561–565, 1990. View at Scopus
22. D. Shibata, G. Capella, and M. Perucho, “Mutational activation of the c-K-ras gene in human pancreatic carcinoma,” Bailliere's Clinical Gastroenterology, vol. 4, no. 1, pp. 151–169, 1990. View at Publisher · View at Google Scholar · View at Scopus
23. V. K. Shukla, D. C. Hughes, L. E. Hughes, F. McCormick, and R. A. Padua, “ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development,” Oncogene Research, vol. 5, no. 2, pp. 121–127, 1989. View at Scopus
24. E. R. Fearon and B. Vogelstein, “A genetic model for colorectal tumorigenesis,” Cell, vol. 61, no. 5, pp. 759–767, 1990. View at Publisher · View at Google Scholar · View at Scopus
25. H. Yamamoto, H. Sawai, T. K. Weber, M. A. Rodriguez-Bigas, and M. Perucho, “Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer,” Cancer Research, vol. 58, no. 5, pp. 997–1003, 1998. View at Scopus
26. L. Losi, M. Ponz de Leon, and M. Ponz de Leon, “K-ras and p53 mutations in hereditary non-polyposis colorectal cancers,” International Journal of Cancer, vol. 74, no. 1, pp. 94–96, 1997. View at Publisher · View at Google Scholar · View at Scopus
27. Y. M. C. Hendriks, A. E. de Jong, and A. E. de Jong, “Diagnostic approach and management of Lynch syndrome (Hereditary Nonpolyposis Colorectal Carcinoma): a guide for clinicians,” CA: A Cancer Journal for Clinicians, vol. 56, no. 4, pp. 213–225, 2006. View at Publisher · View at Google Scholar · View at Scopus
28. D. M. Graham and H. D. Appelman, “Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator,” Modern Pathology, vol. 3, no. 3, pp. 332–335, 1990. View at Scopus
29. S. Popat, R. Hubner, and R. S. Houlston, “Systematic review of microsatellite instability and colorectal cancer prognosis,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 609–618, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
30. R. Dolcetti, A. Viel, and A. Viel, “High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability,” American Journal of Pathology, vol. 154, no. 6, pp. 1805–1813, 1999. View at Scopus
31. K. M. Drescher, P. Sharma, P. Watson, Z. Gatalica, S. N. Thibodeau, and H. T. Lynch, “Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer,” Familial Cancer, vol. 8, no. 3, pp. 231–239, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. M. W. Bennett, J. O'Connell, G. C. O'Sullivan, C. Brady, D. Roche, J. Kevin Collins, and F. Shanahan, “The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma,” Journal of Immunology, vol. 160, no. 11, pp. 5669–5675, 1998. View at Scopus
33. B. Fisk, B. W. Anderson, and B. W. Anderson, “Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes,” Cancer Research, vol. 57, no. 1, pp. 87–93, 1997. View at Scopus
34. R. Sankila, L. A. Aaltonen, H. J. Jarvinen, and J.-P. Mecklin, “Better survival rates in patients with MLH1-associated hereditary colorectal cancer,” Gastroenterology, vol. 110, no. 3, pp. 682–687, 1996. View at Publisher · View at Google Scholar · View at Scopus
35. M. S. Rhyu, “Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma,” Journal of the National Cancer Institute, vol. 88, no. 5, pp. 240–251, 1996. View at Publisher · View at Google Scholar · View at Scopus
36. J. V. Frei, “Hereditary nonpolyposis colorectal cancer (Lynch syndrome II): diploid malignancies with prolonged survival,” Cancer, vol. 69, no. 5, pp. 1108–1111, 1992. View at Scopus
37. M. Kouri, A. Laasonen, J.-P. Mecklin, H. Jarvinen, K. Franssila, and S. Pyrhonen, “Diploid predominance in hereditary nonpolyposis colorectal carcinoma evaluated by flow cytometry,” Cancer, vol. 65, no. 8, pp. 1825–1829, 1990. View at Scopus
38. E. J. Foley, “Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin,” Cancer Research, vol. 13, pp. 835–837, 1953.
39. D. Murray, A. Hreno, J. Dutton, and L. G. Hampson, “Prognosis in colon cancer. A pathologic reassessment,” Archives of Surgery, vol. 110, no. 8, pp. 908–913, 1975. View at Scopus
40. B. Mann, A. Gratchev, and A. Gratchev, “FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas,” British Journal of Cancer, vol. 79, no. 7-8, pp. 1262–1269, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. A. Buckowitz, H.-P. Knaebel, and H.-P. Knaebel, “Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases,” British Journal of Cancer, vol. 92, no. 9, pp. 1746–1753, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. S. Le Gouvello, S. Bastuji-Garin, and S. Bastuji-Garin, “High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas,” Gut, vol. 57, no. 6, pp. 772–779, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. M. Morris, C. Platell, and B. Iacopetta, “Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy,” Clinical Cancer Research, vol. 14, no. 5, pp. 1413–1417, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. M. W. Bennett, J. O'Connell, and J. O'Connell, “Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer,” Gut, vol. 44, no. 2, pp. 156–162, 1999. View at Scopus
45. K. Okada, K. Komuta, S. Hashimoto, S. Matsuzaki, T. Kanematsu, and T. Koji, “Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis,” Clinical Cancer Research, vol. 6, no. 9, pp. 3560–3564, 2000. View at Scopus
46. K. Okano, T. Maeba, and T. Maeba, “Lymphocytic infiltration surrounding liver metastases from colorectal cancer,” Journal of Surgical Oncology, vol. 82, no. 1, pp. 28–33, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. T. C. Smyrk, P. Watson, K. Kaul, and H. T. Lynch, “Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma,” Cancer, vol. 91, no. 12, pp. 2417–2422, 2001. View at Publisher · View at Google Scholar · View at Scopus
48. F. Prall, T. Dührkop, V. Weirich, C. Ostwald, P. Lenz, H. Nizze, and M. Barten, “Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability,” Human Pathology, vol. 35, no. 7, pp. 808–816, 2004. View at Publisher · View at Google Scholar · View at Scopus
49. A. G. Menon, C. M. Janssen-van Rhijn, and C. M. Janssen-van Rhijn, “Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis,” Laboratory Investigation, vol. 84, no. 4, pp. 493–501, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. F. Pagès, A. Kirilovsky, and A. Kirilovsky, “In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5944–5951, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. H. T. Lynch and A. de la Chapelle, “Hereditary colorectal cancer,” New England Journal of Medicine, vol. 348, no. 10, pp. 919–932, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
52. H. Hampel, W. L. Frankel, and W. L. Frankel, “Feasibility of screening for Lynch syndrome among patients with colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5783–5788, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus